Most Recent Articles by Bryant Furlow
Radiogenomics is maturing into a predictor of patients' likelihood of experiencing radiotoxicities and late radiation effects.
Personalized medicine is changing oncology nursing. This primer explains best practices for collecting and preparing biospecimens used to guide therapy.
Psychosocial decline occurs in an estimated one-third of patients undergoing radiotherapy for cancer. These declines may sometimes be ameliorated by vigilant recognition of the need to refer patients for psychosocial support interventions.
High-dose-rate (HDR) brachytherapy is typically used as a dose-escalating boost for external beam radiotherapy for prostate cancer; however, some researchers believe it might be close to graduating to a viable monotherapy.
Some patients undergoing radiotherapy for cancers of the head, neck, and brain are at risk for endocrinopathies. This article reviews the risks, detection, and management of radiotherapy-induced hypopituitarism.
More Articles by Bryant Furlow
- Study may support active surveillance for favorable intermediate-risk prostate cancer
- New mechanism of acquired resistance to breast cancer drugs discovered
- Two major studies strengthen case for prostate cancer drug before chemotherapy
- Finding a qualified acupuncture practitioner
- New opportunity to treat drug-resistant leukemia discovered
- High-cost blood cancer drugs deliver high value
- Statins increase risk of diabetes in Caucasian men
- Sun damage predisposes pediatric patients to melanoma
- Risk of reproductive cancers increased in daughters of women who smoked during pregnancy
- Older white males with advanced bladder cancer more likely to commit suicide
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|